难治性高血压新药取得突破 阿斯利康潜在重磅疗法Baxdrostat临床试验告捷

Core Viewpoint - AstraZeneca's experimental hypertension drug Baxdrostat has shown significant efficacy in reducing blood pressure in patients with resistant or poorly controlled hypertension, enhancing its development prospects as a potential blockbuster therapy [1] Group 1: Drug Efficacy - In a late-stage clinical trial, patients taking Baxdrostat at two different doses experienced a significant and clinically meaningful reduction in systolic blood pressure after 12 weeks compared to those receiving a placebo [1]